(Q83087790)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16595148%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

title

Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16595148%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16595148%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Massimo Federico

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16595148%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

6

David Alberts

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16595148%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

author name string

Maurie Markman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16595148%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

P Y Liu

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16595148%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Edward Hannigan

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16595148%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

publication date

3 April 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16595148%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16595148%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

103

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16595148%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16595148%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

195-198

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16595148%20AND%20SRC:MED&resulttype=core&format=json

Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer

19 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.024

Optimizing primary chemotherapy in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.024

CA-125: an evolving role in the management of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.024

Tumor markers in the management of patients with ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.024

Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.024

Use of CA-125 to predict survival of patients with ovarian carcinoma. North Thames Cooperative Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.024

Prognostic value of serial CA125 measurements during chemotherapy for patients with advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.024

Prognostic value of CA 125 in advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.024

CA 125 regression after two completed cycles of chemotherapy: lack of prediction for long-term survival in patients with advanced ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.024

A risk model for ovarian carcinoma patients using CA 125: time to normalization renders second-look laparotomy redundant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.024

Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.024

Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.024

Second-line treatment of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.024

Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.024

Weekly carboplatin as a strategy to prevent severe treatment-related emesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.02.024

10.1016/J.YGYNO.2006.02.024

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16595148%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference